A CHKA–PML autophagy checkpoint enables tumors to evade glutamine starvation

R Ruijie Wang (National Synchrotron Radiation Laboratory, State Key Laboratory of Precision and Intelligent Chemistry, School of Nuclear Science and Technology) L Leixi Cao (Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University) X Xianwei He (School of Clinical Medicine, Henan University) R Rick Francis Thorne (Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University) Q Qichen Wu (School of Clinical Medicine, Henan University) C Caoyuan Ding (Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University) J Jinjing Zhang (School of Clinical Medicine, Henan University) M Mengfan Li (State Key Laboratory of Chemical Biology & Center of Pharmaceutics) Z Zeyuan Shi (The Department of Pathology, The First Affiliated Hospital of Zhengzhou University) X Xinyi Dong (Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University) J Jing Li H Hongxiang Li (College of Polymer Science and Engineering State Key Laboratory of Polymer Materials Engineering) S Suhua Gao (Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University) J Jinming Li (Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University) X Xu Dong Zhang (School of Biomedical Sciences and Pharmacy, The University of Newcastle) L Lei Jin T Tianli Fan (Department of Pharmacology, School of Basic Medicine, Zhengzhou University) M Mian Wu (Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University)

Abstract

Glutamine metabolism is essential for tumor cell proliferation and biosynthesis. However, solid tumors often face chronic glutamine deprivation, and the underlying adaptive mechanisms remain incompletely understood. Here, we show that glutamine scarcity upregulates choline kinase alpha (CHKA), whose monomerization enhances its noncanonical protein kinase activity. CHKA phosphorylates promyelocytic leukemia (PML) at tyrosine 339, promoting its cytoplasmic localization. Notably, this reflects a compartment-specific switch in PML activity: while nuclear PML facilitates protein degradation through Small Ubiquitin-like Modifier (SUMO)-ubiquitin cascades, cytoplasmic PML acts oppositely to block degradation. Specifically, cytoplasmic PML then induces SUMOylation of WD Repeat Domain Phosphoinositide-Interacting Protein 2 (WIPI2) at lysines 281 and 283, thereby blocking HUWE1-mediated ubiquitination and proteasomal degradation. Stabilized WIPI2 increases autophagic flux, supporting tumor cell survival under metabolic stress. This study identifies a critical CHKA–PML–WIPI2 axis mediating adaptation to glutamine deprivation, providing insight into metabolic plasticity and a potential therapeutic target for glutamine-dependent cancers.

Article Details

Volume / Issue Vol. 123, Issue 12
Published March 24, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (18)

R

Ruijie Wang

National Synchrotron Radiation Laboratory, State Key Laboratory of Precision and Intelligent Chemistry, School of Nuclear Science and Technology

L

Leixi Cao

Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University

X

Xianwei He

School of Clinical Medicine, Henan University

R

Rick Francis Thorne

Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University

Q

Qichen Wu

School of Clinical Medicine, Henan University

C

Caoyuan Ding

Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University

J

Jinjing Zhang

School of Clinical Medicine, Henan University

M

Mengfan Li

State Key Laboratory of Chemical Biology & Center of Pharmaceutics

Z

Zeyuan Shi

The Department of Pathology, The First Affiliated Hospital of Zhengzhou University

X

Xinyi Dong

Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University

J

Jing Li

H

Hongxiang Li

College of Polymer Science and Engineering State Key Laboratory of Polymer Materials Engineering

S

Suhua Gao

Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University

J

Jinming Li

Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University

X

Xu Dong Zhang

School of Biomedical Sciences and Pharmacy, The University of Newcastle

L

Lei Jin

T

Tianli Fan

Department of Pharmacology, School of Basic Medicine, Zhengzhou University

M

Mian Wu

Translational Research Institute of People’s Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, School of Convergence Medicine, Zhengzhou University